Ask AI
ProCE Banner Activity

ClinicalThought Expert Office Hours Forum: The Next Frontier for CDK4/6 Inhibitors in Breast Cancer - Applying the Latest Guidelines and Advances in Practice

Clinical Thought

Experts answer your questions related to the program, “The Next Frontier for CDK4/6 Inhibitors in Breast Cancer: Expert Strategies for Applying the Latest Guidelines and Advances in Practice.” This social media forum provides you with ongoing access to experts for your questions and challenging cases throughout the certified life of this program.

Released: May 15, 2026

Review Activity

Share

Provided by

Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Decera Clinical Education.

ProCE Banner

Supporters

Supported by educational grants from Lilly and Novartis Pharmaceuticals Corporation.

Lilly

Novartis Pharmaceuticals Corporation

Partners

Decera Clinical Education

ProCE Banner

Target Audience

This activity is intended for oncologists, physician associates (PAs), nurse practitioners (NPs), nurses, pharmacists, and other healthcare professionals who care for patients with breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate current CDK4/6 inhibitor therapies into treatment plans of appropriate patients with HR+/HER2- early breast cancer in alignment with NCCN Guidelines and expert-recommended best practices

  • Align current CDK4/6 inhibitor treatment in patients with HR+/HER2- metastatic breast cancer with NCCN Guidelines and expert-recommended best practices

  • Manage adverse events associated with CDK4/6 inhibitors to foster and optimize treatment adherence, persistence, and enhance overall outcomes of patients with breast cancer

Disclosure

Primary Author

William J. Gradishar, MD, FACP, FASCO: consultant/advisor/speaker: AstraZeneca, Lilly, Merck, Stemline.

Heather McArthur, MD, MPH, FASCO: consultant/advisor/speaker: ALX, AstraZeneca, Boston Scientific, Daiichi Sankyo, Delcath Systems, Genentech/Roche, Gilead, Lilly, Novartis, Pfizer.